drugset / Trial / NCT02569515
A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the tolerability, and effect on quality of life, in patients receiving multi-dose NeoRecormon administered by RecoPen in predialysis patients with chronic renal anemia. The anticipated time on study treatment is 10 months, and the target sample size is 60 individuals.
Timeline
- Start
- 2004-10
- Primary completion
- 2006-07
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 30 iu/kg | Subcutaneous |